Literature DB >> 22586045

Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma.

Emina Babarović1, Toni Valković, Sanja Štifter, Ivana Budisavljević, Irena Seili-Bekafigo, Antica Duletić-Načinović, Ksenija Lučin, Nives Jonjić.   

Abstract

The aim of our study was to emphasize the importance of accurate and standardized techniques for detailed monitoring of the microenvironment in multiple myeloma (MM). Bone marrow fibrosis, angiogenesis, and plasma cell infiltrates in bone marrow biopsy (BMB) samples at the time of diagnosis and on completion of therapy were analyzed for 42 patients with newly diagnosed MM. Computerized image analysis was used for all slides stained with anti-CD138 and anti-CD34. The patients with fibrosis in pretreatment BMB samples had significantly higher microvessel density (MVD) and plasma cell infiltrates. In posttreatment BMB samples, nonresponders had a significantly higher frequency and grade of fibrosis and higher values of MVD, total vascular area, and plasma cell percentage. The overall survival of nonresponders and patients with increased marrow fibrosis in posttreatment BMB samples was significantly shorter. The obtained results confirm that complex morphologic examination of the bone marrow microenvironment during the monitoring of MM can provide better prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22586045     DOI: 10.1309/AJCPT5Y2JRIUUCUB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease.

Authors:  Emanuel Della-Torre; Elena Rigamonti; Cory Perugino; Simona Baghai-Sain; Na Sun; Naoki Kaneko; Takashi Maehara; Lucrezia Rovati; Maurilio Ponzoni; Raffaella Milani; Marco Lanzillotta; Vinay Mahajan; Hamid Mattoo; Ivan Molineris; Vikram Deshpande; John H Stone; Massimo Falconi; Angelo A Manfredi; Shiv Pillai
Journal:  J Allergy Clin Immunol       Date:  2019-07-15       Impact factor: 10.793

2.  Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease.

Authors:  Megumi Koshiishi; Ichiro Kawashima; Hideto Hyuga; Ayato Nakadate; Minori Matsuura; Eriko Hosokawa; Yuma Sakamoto; Jun Suzuki; Megumi Suzuki; Takuma Kumagai; Takeo Yamamoto; Kei Nakajima; Masaru Tanaka; Keita Kirito
Journal:  Int J Hematol       Date:  2022-05-10       Impact factor: 2.319

3.  Diagnostic value of bone marrow aspiration and biopsy in routine hematology practice.

Authors:  Manjit Kaur; Amrit Pal Singh Rana; Shivali Kapoor; Arun Puri
Journal:  J Clin Diagn Res       Date:  2014-08-20

4.  Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.

Authors:  Nuri Lee; Hyewon Lee; Soo Young Moon; Ji Yeon Sohn; Sang Mee Hwang; Ok Jin Yoon; Hye Sun Youn; Hyeon Seok Eom; Sun Young Kong
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

5.  Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma.

Authors:  Toni Valković; Emina Babarović; Ksenija Lučin; Sanja Štifter; Merica Aralica; Irena Seili-Bekafigo; Antica Duletić-Načinović; Nives Jonjić
Journal:  Biomed Res Int       Date:  2016-01-27       Impact factor: 3.411

6.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

7.  Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma

Authors:  Ahmet Şeyhanlı; Boran Yavuz; Zehra Akşit; Zeynep Yüce; Sermin Özkal; Oğuz Altungöz; Fatih Demirkan; İnci Alacacıoğlu; Güner Hayri Özsan
Journal:  Turk J Haematol       Date:  2021-11-26       Impact factor: 2.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.